BelHealth acquires Precision Toxicology

Healthcare-focused private equity firm BelHealth Investment Partners has acquired Precision Toxicology. Headquartered in San Diego, California, the company is a clinical laboratory that specializes in providing quantitative drug testing, primarily for the purpose of helping physicians monitor their patients undergoing treatment for pain or substance abuse.

PRESS RELEASE

BelHealth Investment Partners (“BelHealth”), a healthcare-focused private
equity firm, announced today the acquisition of Precision Toxicology (“Precision” or the “Company”).
Precision, headquartered in San Diego, California, is a clinical laboratory that specializes in providing
quantitative drug testing, primarily for the purpose of helping physicians monitor their patients undergoing
treatment for pain or substance abuse. Precision’s objective is to improve patient adherence/compliance
with their prescription regimen and protect medical practices from liability. The Company has experienced
rapid growth since inception and will continue to expand its successful strategy throughout the rest of the
country, becoming a leading, national clinical toxicology lab.
Dennis Drislane, BelHealth Managing Partner, stated, “Toxicology is one of the fastest growing segments
of the laboratory industry. We have evaluated several companies in the segment and determined that
Precision offers the best opportunity to take advantage of the market tailwinds and build a leading, national
toxicology lab. Precision is managed by two young entrepreneurs, Jason Hansen and Miguel Gallego, who
understand the importance of strong compliance and operating a business the right way in a highly
scrutinized industry. Jason and his team are incredibly talented and with the right infrastructure to support
them, have the potential for exponential growth. We are thrilled about the potential of this investment
partnership.”
Precision is BelHealth’s fifth platform company, and is a great fit because of the enormous synergy
opportunities between Precision and some of the other BelHealth portfolio companies. For example,
Linden Care, the leading specialty pharmacy in the U.S. with a focus on pain pharmaceuticals, has nearly
5,000 relationships with physicians that routinely prescribe pain medications. Precision will leverage
Linden Care’s physician relationships to cross sell its drug testing services. As another example, General
Genetics Corporation (GGC), a clinical genetic testing laboratory, provides pharmacogenetic testing that
helps physicians understand how rapidly a patient metabolizes pain medications. There is an opportunity
for Precision, Linden Care and GGC to not only benefit from cross selling, but to create a comprehensive
pain management solution. This solution would be unique in the market and appeal to physicians, to help
guide better treatment decisions, and payors, which are seeking to control the rapid rise in cost of pain
management.
126 East 56th Street, 10th Floor 4100 Newport Place, Suite 255 26 Harbor Park Drive
New York, NY 10022 Newport Beach, CA 92660 Port Washington, NY 11050
T: 347‐308‐7011 T: 949‐200‐6547 T: 516‐626‐5678